Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2026 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.56M$5.56Mderived+48.1% vs Q4 2025 Net Income-$581.00K-$581.00KderivedN/M vs Q4 2025 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,181,000+42.7% Operating Incomederived-$351,000N/M Operating Cash Flowderived-$519,000N/M Free Cash Flowderived-$548,000N/M Margins · derivedGross margin39.2%−1.5 pt vs Q4 2025
Operating margin-6.3%+11.2 pt vs Q4 2025
Net margin-10.4%+10.2 pt vs Q4 2025
ended Mar 31, 2026 · filed Jun 16, 2026 · 77 d after period end